TruSight Oncology Comprehensive (EU): A new era for better patient outcomes

In this brochure, Illumina highlights TruSight™ Oncology Comprehensive (EU), a next-generation sequencing solution that enables institutions to offer in-house comprehensive genomic profiling for cancer, emphasizing its clinically relevant biomarker coverage, alignment with drug labels and European Society for Medical Oncology (ESMO) recommendations. By implementing the test in-house, labs gain control over sample logistics and data management, improve sample QC and biomarker-informed case rates, and strengthen their role as precision medicine providers.